Amniotic-Derived Exosomes in Clinical Practice: Safety and Outcomes in 608 Patients

Introduction: Exosomes from amniotic sources offer promising immunomodulatory and regenerative potential in various conditions, but large-scale human safety data are limited. This study reports safety and observational outcomes in a large cohort treated with amniotic-derived exosomes, often combined with PRF/ALB-PRF. Methods: Retrospective analysis of 608 patients (aged 25-84, ~50% male/ female) treated between August 2023 and July 2025 for musculoskeletal and systemic conditions. Exosomes (4 trillion) were administered IV and/ or locally with PRF/ALB-PRF. Safety was monitored via follow-ups; outcomes assessed descriptively. Results: No serious adverse events or allergic reactions occurred (95% CI for SAE rate: 0%-0.63%). Mild inflammation affected 30% of PRF/ALBPRF recipients (95% CI: 26.0%-34.4%; resolving within a week), with four flare-ups lasting up to one month. Common transient side effects: tiredness (10%, 95% CI: 7.9%-12.7%), general joint pain (10%, 95% CI: 7.9%- 12.7%), increased resting pulse (5%, 95% CI: 3.5%-7.0%). Satisfactory symptom relief was reported by 85% of patients; 10% saw positive but unsatisfactory effects; 5% had no relief. Demographics showed mean age 54.39 ± 9.22 years, with no significant group differences. Conclusion: Amniotic-derived exosomes are safe and well-tolerated, supporting their use in regenerative medicine. This large dataset provides real-world evidence for further trials.